Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis

International Journal of Rheumatic Diseases

Volumn 20, Issue 9, 2017, Pages 1277-1285

  Lomax, Anna J ^a   McGuire, Helen M ^b,c   McNeil, Catriona ^a,b,d   Choi, Clara J ^b,c   Hersey, Peter ^c,e   Karikios, Deme ^a,f   Shannon, Kerwin ^a,b,d,e   van Hal, Sebastian ^b,d   Carr, Urszula ^g   Crotty, Anne ^h   Gupta, Sandeep K ^i,j   Hollingsworth, Jane ^b,d   Kim, Haewon ^b,d   Fazekas de St Groth, Barbara ^b,c   McGill, Neil ^b,d  

^a Chris O'Brien Lifehouse   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CENTENARY INSTITUTE   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e MELANOMA INSTITUTE AUSTRALIA   (Australia)

^f NEPEAN HOSPITAL   (Australia)

^g Kossard Dermatopathologists   (Australia)

^h Pathology North   (Australia)

ⁱ JOHN HUNTER HOSPITAL   (Australia)

^j UNIVERSITY OF NEWCASTLE   (Australia)

more..

Author keywords

melanoma; nivolumab; pembrolizumab; programmed cell death 1; sarcoidosis

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; IPILIMUMAB; NIVOLUMAB; PD 1 CHECKPOINT INHIBITOR; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ANOREXIA; ARTICLE; BIOPSY; CANCER STAGING; CANCER SURGERY; CASE REPORT; CASE STUDY; CLINICAL ARTICLE; DISEASE COURSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; MASS CYTOMETRY; MEDICAL RECORD REVIEW; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; SARCOIDOSIS; TH17 CELL; TH17.1 CELL; THYROIDITIS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; LUNG SARCOIDOSIS; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SECONDARY; SKIN TUMOR; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS; BIOPSY; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGRAMMED CELL DEATH 1 RECEPTOR; SARCOIDOSIS, PULMONARY; SKIN NEOPLASMS; TH17 CELLS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85019039777     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.13076     Document Type: Article

References (32)

1. Robert C, Schachter J, Long GV et al. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372, 2521–32.
2. Larkin J, Chiarion-Sileni V, Gonzalez R et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (1), 23–34.
3. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. (2016) Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol 34 (Suppl), abstr 9505.
4. Robert C, Ribas A, Hamid O et al. (2016) Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 34 (Suppl); abstr 9503.
5. Ribas A (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366, 2517–9.
6. O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110, 2614–27.
7. Long GV, Atkinson VG, Cebon J et al. (2016) Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort. J Clin Oncol 34 (Suppl), abstr 9506.
8. Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F (2016) Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract pii: 1078155216667635. [Epub ahead of print].
9. Danlos FX, Pages C, Baroudjian B et al. (2016) Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest 149 (5), e133–6.
10. Montaudie H, Pradelli J, Passeron T, Lacour JP, Leroy S (2016) Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol Doi: 10.1111/bjd.14808. [Epub ahead of print].
11. Cousin S, Toulmonde M, Kind M et al. (2016) Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol 27, 1178–9.
12. Berthod G, Lazor R, Letovanec I et al. (2012) Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 30 (17), e156–9.
13. Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, Blank CU (2012) Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 30 (2), e7–e10.
14. Murphy KP, Kennedy MP, Barry JE, O'Regan KN, Power DG (2014) New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 37, 351–3.
15. Wahlstrom J, Katchar K, Wigzell H, Olerup O, Eklund A, Grunewald J (2001) Analysis of intracellular cytokines in CD4 + and CD8 + lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 163 (1), 115–21.
16. Facco M, Cabrelle A, Teramo A et al. (2011) Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 66 (2), 144–50.
17. Ten Berge B, Paats MS, Bergen IM et al. (2012) Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford) 51 (1), 37–46.
18. Acosta-Rodriguez EV, Rivino L, Geginat J et al. (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8, 639–46.
19. Ramesh R, Kozhaya L, McKevitt K et al. (2014) Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 211 (1), 89–104.
20. Ramstein J, Broos CE, Simpson LJ et al. (2016) IFN-γ-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med 193, 1281–91.
21. Bendall SC, Simonds EF, Qiu P et al. (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332, 687–96.
22. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM (2012) Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8 + T cell phenotypes. Immunity 36 (1), 142–52.
23. Fistarol SK, Itin PH (2013) Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol 14 (1), 27–47.
24. Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357, 2153–65.
25. Baughman RP, Culver DA, Judson MA (2011) A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 183, 573–81.
26. Beutler BD, Cohen PR (2015) Sarcoidosis in melanoma patients: case report and literature review. Cancers (Basel) 7, 1005–21.
27. von Euw E, Chodon T, Attar N et al. (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7, 35. DOI: 10.1186/1479-5876-7-35
28. Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8, 345–50.
29. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10, 864–71.
30. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR (2008) Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 58, 875–87.
31. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236, 219–42.
32. Braun NA, Celada LJ, Herazo-Maya JD et al. (2014) Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med 190, 560–71.